Unknown

Dataset Information

0

PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells.


ABSTRACT: Glioblastoma (GBM) is the most lethal primary brain cancer that lacks effective molecular targeted therapies. The PI3K/AKT/mTOR pathway is activated in 90% of all Glioblastoma multiforme (GBM) tumors. To gain insight into the impact of the PI3K pathway on GBM metabolism, we treated U87MG GBM cells with NVP-BEZ235 (PI3K and mTOR a dual inhibitor) and identified differentially expressed genes with RNA-seq analysis. RNA-seq identified 7803 differentially regulated genes in response to NVP-BEZ235. Gene Set Enrichment Analysis (GSEA) identified two glycolysis-related gene sets that were significantly enriched (p < 0.05) in control samples compared to NVP-BEZ235-treated samples. We validated the inhibition of glycolytic genes by NVP-BEZ235 and examined the impact of the FOXO1 inhibitor (AS1842856) on these genes in a set of GBM cell lines. FOXO1 inhibition alone was associated with reduced LDHA expression, but not ENO1 or PKM2. Bioinformatics analyses revealed that PI3K-impacted glycolytic genes were over-expressed and co-expressed in GBM clinical samples. The elevated expression of PI3K-impacted glycolytic genes was associated with poor prognosis in GBM based on Kaplan-Meier survival analyses. Our results suggest novel insights into hallmark metabolic reprogramming associated with the PI3K-mTOR dual inhibition.

SUBMITTER: Udawant S 

PROVIDER: S-EPMC8616488 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3947495 | biostudies-literature
| S-EPMC5503517 | biostudies-literature
| S-EPMC3610553 | biostudies-literature
| S-EPMC3471922 | biostudies-literature
| S-EPMC8784527 | biostudies-literature
| S-EPMC5542201 | biostudies-literature
| S-EPMC3964191 | biostudies-literature
| S-EPMC7057587 | biostudies-literature
2021-12-01 | GSE179667 | GEO
| S-EPMC3360787 | biostudies-literature